Galmed Accelerates Heart Failure Innovation with Aramchol
RAMAT-GAN, Israel, July 16, 2026 Galmed Pharmaceuticals Ltd. has announced the breakthrough development of a novel lipid nanoparticle (LNP)...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
RAMAT-GAN, Israel, July 16, 2026 Galmed Pharmaceuticals Ltd. has announced the breakthrough development of a novel lipid nanoparticle (LNP)...
FLAGSTAFF, Ariz., May 11, 2026 Corvention announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance...
FORT MILL, S.C., March 6, 2026 Catheter Precision, Inc., a U.S.-based medical technology company specializing in cardiac electrophysiology innovations,...
Houston, Texas | January 2026 — HeartX, a leading cardiovascular innovation accelerator, has officially opened applications for its 2026...
Princeton, N.J., November 4, 2025 – Bristol Myers Squibb (NYSE: BMY) announced a major scientific milestone with the presentation...
